Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.59 |
| ▸ | LMNA | P02545 | 3/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | EGFR | P00533 | 6/20 | 0.48 |
| ▸ | ERBB2 | P04626 | 6/20 | 0.48 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | RORC | P51449 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20296965 | 1.00 | MEN1 (0.59) | MEN1KMT2ALMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL18709336 | 0.90 | CA12 (0.55) | MEN1KMT2ALMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL20296990 | 0.90 | CA12 (0.55) | MEN1KMT2ALMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL18709367 | 0.90 | TSHR (0.56) | MEN1KMT2ALMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL20296961 | 0.90 | TSHR (0.56) | MEN1KMT2ALMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL17329206 | 0.89 | PRMT1 (0.55) | MEN1KMT2ALMNAMAPTRORC | |
| SCHEMBL17329205 | 0.89 | PRMT1 (0.55) | MEN1KMT2ALMNAMAPTRORC | |
| SCHEMBL17329224 | 0.84 | MEN1 (0.47) | MEN1KMT2ALMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL17329223 | 0.84 | MEN1 (0.47) | MEN1KMT2ALMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL20296969 | 0.84 | CA12 (0.57) | MEN1KMT2ALMNASMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180179193-A1 | N-Sulfonyl Homoserine Lactone Derivatives, Preparation Method and Use Thereof | INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY ACADEMY OF MILITARY MEDICAL SCIENCES P.L.A. CHINA (CN) | 2018-06-28 | — | — | US | disclosed |
| EP-3150594-A1 | N-SULFONYL HOMOSERINE LACTONE DERIVATIVES, PREPARATION METHOD THEREFOR AND USE | Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. China (CN) | 2017-04-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180179193-A1 | N-Sulfonyl Homoserine Lactone Derivatives, Preparation Method and Use Thereof | LSS, SOS1, STS | MEN1 346/4885KMT2A 3793/4885LMNA 1575/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.